Pacira BioSciences Q1 2026 Earnings Call Transcript

robot
Abstract generation in progress

Pacira BioSciences reported strong Q1 2026 results, driven by their “5 by 30” strategy, which focuses on patients served, product, revenue, profitability, pipeline, and partnerships. Flagship product Exparel saw renewed growth with a 7% volume increase, supported by expanded reimbursement and intellectual property protection. Zilretta and Iovera also experienced sales growth of 15% and 21% respectively, due to dedicated sales forces and strategic collaborations, with key clinical milestones anticipated for PCRX201 and PCRX2002 later this year.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin